APA (7th ed.) Citation

de Groot, S., Pijl, H., Charehbili, A., van de Ven, S., Smit, V. T. H. B. M., Meershoek-Klein Kranenbarg, E., . . . Kroep, J. R. (2019). Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01). Breast cancer research : BCR, 21(1), 97-9. https://doi.org/10.1186/s13058-019-1180-6

Chicago Style (17th ed.) Citation

de Groot, Stefanie, et al. "Addition of Zoledronic Acid to Neoadjuvant Chemotherapy Is Not Beneficial in Patients with HER2-negative Stage II/III Breast Cancer: 5-year Survival Analysis of the NEOZOTAC Trial (BOOG 2010-01)." Breast Cancer Research : BCR 21, no. 1 (2019): 97-9. https://doi.org/10.1186/s13058-019-1180-6.

MLA (9th ed.) Citation

de Groot, Stefanie, et al. "Addition of Zoledronic Acid to Neoadjuvant Chemotherapy Is Not Beneficial in Patients with HER2-negative Stage II/III Breast Cancer: 5-year Survival Analysis of the NEOZOTAC Trial (BOOG 2010-01)." Breast Cancer Research : BCR, vol. 21, no. 1, 2019, pp. 97-9, https://doi.org/10.1186/s13058-019-1180-6.